- Tuesday, April 21st 2020 at 16:00 - 17:00 UK (Other timezones)
- General participation info | Participate online | + Phone in United States (Toll Free): 1 877 309 2073 United States: +1 (571) 317-3129 Australia (Toll Free): 1 800 193 385 Australia: +61 2 8355 1020 Austria (Toll Free): 0 800 202148 Belgium (Toll Free): 0 800 78884 Canada (Toll Free): 1 888 455 1389 Denmark (Toll Free): 8090 1924 France (Toll Free): 0 805 541 047 Germany (Toll Free): 0 800 184 4222 Greece (Toll Free): 00 800 4414 3838 Hungary (Toll Free): (06) 80 986 255 Iceland (Toll Free): 800 9869 Ireland (Toll Free): 1 800 946 538 Israel (Toll Free): 1 809 454 830 Italy (Toll Free): 800 793887 Japan (Toll Free): 0 120 663 800 Luxembourg (Toll Free): 800 22104 Netherlands (Toll Free): 0 800 020 0182 New Zealand (Toll Free): 0 800 47 0011 Norway (Toll Free): 800 69 046 Poland (Toll Free): 00 800 1213979 Portugal (Toll Free): 800 819 575 Spain (Toll Free): 800 900 582 Sweden (Toll Free): 0 200 330 905 Switzerland (Toll Free): 0 800 740 393 United Kingdom (Toll Free): 0 800 169 0432 Access Code: 731-636-357
Subjects with a diagnosis of schizophrenia show consistent differences from controls in neuroimaging paradigms such as resting state (rsEEG and rsfMRI), mismatch negativity (MMN) and 40 Hz auditory steady state response (ASSR). The underlying circuit changes causing these group differences are unclear, however, and it is not known whether the same abnormalities could underlie group differences in all paradigms. Nevertheless, it is widely hypothesised that schizophrenia involves a loss of synaptic gain – e.g. due to NMDA receptor dysfunction – and disrupted balance between excitatory and inhibitory transmission in cortical circuits. Here we analyse a neuroimaging dataset containing data from controls (n=107), subjects diagnosed with schizophrenia (Scz, n=108) and their first degree relatives (n=57) each undergoing rsEEG, rsfMRI, MMN and 40 Hz ASSR paradigms. We use a variety of dynamic causal modelling approaches to estimate synaptic gain and other circuit parameters in auditory and frontal areas. We find some striking commonalities across paradigms, not just in synaptic gain in the Scz group, but also in relationships with symptoms and cognitive function. The potential for development of a model-based biomarker of synaptic gain is discussed.
Dr. Rick Adams
Research Fellow
Centre for Medical Image Computing
Dept of Computer Science
University College London
